Aclaris Therapeutics Inc.

09/17/2024 | Press release | Distributed by Public on 09/17/2024 05:42

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to[...]